Impax Pharmaceuticals (NASDAQ:IPXL) is to reveal details of its recent clinical trials for the Parkinson's disease treatment Rytary. The unveiling will occur on March 18 at the American Academy of Neurology conference in San Diego. The company has conducted phase III and open-label extension trials for the drug.
Impax describes Rytary as a "formulation of cabidopa-levodopa for the treatment of idiopathic Parkinson's disease."
The company has had its difficulties lately, with the Food and Drug Administration raising numerous points of concern about its Hayward, California facilities in the regulator's findings of the firm's pre-approval and good manufacturing practices.
Fool contributor Eric Volkman has no position in Impax Pharmaceuticals. The Motley Fool has no position in Impax Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.